News

C4 Therapeutics Welcomes Stephen Fawell, Ph.D. to Leadership

C4 Therapeutics Welcomes Stephen Fawell, Ph.D. to Leadership

Exciting Leadership Changes at C4 Therapeutics

C4 Therapeutics, Inc. (NASDAQ: CCCC), a pioneering clinical-stage biopharmaceutical company, has shared important news regarding its Board of Directors. Stephen (Steve) Fawell, Ph.D., a highly experienced leader in the biotechnology field, has joined the board, bringing with him nearly 35 years of invaluable expertise in drug discovery. This announcement comes as Malcolm Salter, who has served on the board for nearly a decade, prepares to retire.

Welcoming Steve Fawell, Ph.D.

Andrew Hirsch, the president and CEO of C4 Therapeutics, expressed his excitement about Dr. Fawell's appointment, highlighting his vast experience in shaping strategies within global pharmaceutical companies. "Steve’s impressive background in drug discovery and development aligns perfectly with our mission to create groundbreaking degrader medicines that could transform the lives of patients facing serious diseases," said Hirsch.

Appreciation for Malcolm Salter

Hirsch also took a moment to recognize the significant contributions made by Malcolm Salter during his time on the board. Since the founding of C4 Therapeutics in 2015, Salter has played a crucial role in transitioning the company to a publicly traded entity and in guiding several therapies into the clinical phase. His leadership has cultivated a strong culture that continues to attract top talent in the industry.

Dr. Fawell's Vision for C4 Therapeutics

Reflecting on his new position, Dr. Fawell shared his enthusiasm for C4 Therapeutics’ innovative approach to targeted protein degradation. "Having followed the company for some time, I’m eager to support our management team in advancing our cutting-edge portfolio and reaching significant milestones in drug development. We have the potential to positively impact the lives of many patients with our focused strategy," he remarked.

Impressive Background in Biotechnology

Dr. Fawell boasts an impressive resume, with extensive experience across various therapeutic areas, including oncology and virology. In his previous role as vice president and head of oncology small molecule drug discovery at AstraZeneca, he was instrumental in transitioning over 25 new drugs into clinical development. This included advanced projects such as camizestrant and saruparib, as well as support for notable drugs like Tagrisso, Lynparza, Calquence, and Truqap.

C4 Therapeutics' Commitment to Innovation

C4 Therapeutics is making remarkable progress in the realm of targeted protein degradation, employing its proprietary TORPEDO platform to develop advanced therapies. The company is dedicated to discovering and optimizing small-molecule medicines aimed at tackling diseases that are notoriously challenging to treat.

Advancing Patient Outcomes

The primary objective of C4 Therapeutics is to create degrader medicines that harness the body's natural protein recycling mechanisms. This innovative strategy not only has the potential to address challenges related to drug resistance and undruggable targets but also aims to enhance overall patient outcomes.

Frequently Asked Questions

What is the role of Stephen Fawell at C4 Therapeutics?

Stephen Fawell, Ph.D., has been appointed to the Board of Directors, where he will help steer the company's strategic direction, particularly in the area of drug discovery.

Why is Malcolm Salter leaving the Board of Directors?

Malcolm Salter has chosen to retire after nearly ten years of dedicated service, during which he made significant contributions to the growth and success of C4 Therapeutics.

What is the focus of C4 Therapeutics?

C4 Therapeutics is focused on developing therapies centered on targeted protein degradation, aimed at treating challenging diseases, and utilizes its TORPEDO platform for innovative drug design.

What achievements does Dr. Fawell have in drug development?

Dr. Fawell has an impressive track record, having successfully advanced multiple investigational new drugs into clinical trials during his previous roles, particularly at AstraZeneca and Merck.

How does targeted protein degradation work?

Targeted protein degradation leverages the body's natural processes to eliminate disease-causing proteins, presenting a promising strategy for overcoming treatment challenges in various diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 34

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 112

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 140

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 79

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion180 Unveils Innovative Customizable Flood Insurance

Updated Category News Views 177

Orion180 Launches Customizable Residential Flood Insurance Orion180 is making waves in the insurance sector by introducing its latest offering: a Residential Private Flood Insurance product designed to meet a variety of homeowner needs. Based in Melbourne, this innovative insurance leader is set to change how we approach flood insurance with a product that emphasizes...

Continue Reading
DIFD AUTO Revolutionizes Global Car Buying with Crypto Payments

Updated Category News Views 306

Transforming the Car Buying Experience with Cryptocurrency Today, as the digital landscape continues to evolve, DIFD AUTO stands at the forefront of a revolutionary shift in how consumers purchase vehicles. As a leading platform for cryptocurrency-based car transactions, DIFD AUTO allows customers around the globe to purchase brand-new, certified cars using major...

Continue Reading
Curtiss-Wright Reports Impressive Q3 Results and Outlook Boost

Updated Category News Views 102

Curtiss-Wright's Positive Financial Performance Curtiss-Wright Corporation (NYSE: CW) is a well-known global company recognized for providing highly engineered products and services. Recently, the company reported noteworthy financial results for the third quarter. The sales surged nearly 10% year-over-year, coming close to $800 million, with exceptional growth especially...

Continue Reading
Darling Ingredients Reports Q3 2024 Results Amid Challenges

Updated Category News Views 312

Third Quarter 2024 Overview Darling Ingredients Inc. today reported net income of $16.9 million, or $0.11 per diluted share for the third quarter of 2024. This represents a significant decline compared to net income of $125.0 million, or $0.77 per diluted share, in the third quarter of 2023. The notable decrease in net income is attributed to lower fat prices and reduced...

Continue Reading
Investigation Launched for Investors of Spyre Therapeutics, Inc.

Updated Category News Views 127

Investigation Launched into Spyre Therapeutics, Inc. Pomerantz LLP has announced an investigation on behalf of investors of Spyre Therapeutics, Inc., known by its stock ticker, NASDAQ: SYRE. This inquiry stems from allegations that the company, along with some of its executives and board members, may have been involved in securities fraud or engaged in other unlawful...

Continue Reading